Therefore, targeting c-Myc may represent a promising approach against aggressive cancers such PEL and MM that, although different, share some similarities such as the presence of basal ER stress, the constitutive activation of oncogenic pathways such as STAT3 and Wnt/B-catenin and the overexpression c-Myc. The gene discussed is MYC; the disease is Miyoshi myopathy.